ATRA — Atara Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1604464 ·
Last close
$9.61
Market Cap
$86.59M
52W High
$12.45
52W Low
$4.30
ADV30
2,850,201
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 516,000 | 392,000 | -3,369,000 | -4,145,000 | 19,997,000 | 8,360,000 | 57,309,000 |
| Dec 2025 | 1,595,000 | 1,491,000 | -2,563,000 | -3,406,000 | 20,235,000 | 8,482,000 | 58,737,000 |
| Sep 2025 | 3,453,000 | 3,338,000 | -3,574,000 | -4,303,000 | 30,167,000 | 5,742,000 | 66,801,000 |
| Jun 2025 | 17,575,000 | 17,021,000 | 3,776,000 | 2,387,000 | 36,902,000 | 16,903,000 | 71,943,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-50,940,000
Investing CF
$18,148,000
Financing CF
$16,098,000
CapEx
$-90,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.18
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,021,865,000
Inventory
$0
Receivables
$1,253,000
ST Investments
$0
EBIT TTM
$36,511,000
Pretax Income TTM
$32,719,000
Interest Exp TTM
$3,792,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$23,139,000
EBITDA
$7,650,000
Free Cash Flow
$-6,391,625
Enterprise Value
$89,015,688
Total Cash
$8,360,000
Total Debt
$9,076,000
Shares Out
9,010,172
Trailing EPS
$-1.20
Book Value
$-4.38
ROE
—
ROA
11.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 120,772,000 | 35,862,000 | 32,688,000 | 20,235,000 | 58,737,000 | — | -50,940,000 |
| Dec 2024 | 128,940,000 | -83,438,000 | -85,403,000 | 109,098,000 | 206,381,000 | — | -68,717,000 |
| Dec 2023 | 8,573,000 | -276,006,000 | -276,126,000 | 165,504,000 | 264,735,000 | — | -192,977,000 |
| Dec 2022 | 63,573,000 | -280,513,000 | -228,302,000 | 376,420,000 | 249,780,000 | — | -270,430,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.64
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXOZ | EXOZYMES INC. | $84.03M | $9.91 | — |
| OKYO | OKYO Pharma Ltd | $89.74M | $1.71 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $83.11M | $5.99 | — |
| LONA | LeonaBio, Inc. | $90.84M | $9.67 | — |
| PTHS | Pelthos Therapeutics Inc. | $94.43M | $27.17 | — |
News headlines (Yahoo Finance, 1h cache)
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
2026-05-21 14:37 · Yahoo
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
2026-05-12 20:05 · Yahoo
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
2026-05-07 15:03 · Yahoo
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
2026-05-07 12:05 · Yahoo
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
2026-04-03 00:02 · Yahoo
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
2026-04-01 12:01 · Yahoo
Atara Biotherapeutics: Q4 Earnings Snapshot
2026-03-16 20:35 · Yahoo
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
2026-03-16 20:05 · Yahoo
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
2026-03-03 11:52 · Yahoo
Atara Biotherapeutics Provides a Business Update
2026-02-23 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.